XNAS:ACUR Acura Pharmaceuticals Inc Quarterly Report 10-Q/A Filing - 6/30/2012

Effective Date 6/30/2012

XNAS:ACUR Fair Value Estimate
Premium
XNAS:ACUR Consider Buying
Premium
XNAS:ACUR Consider Selling
Premium
XNAS:ACUR Fair Value Uncertainty
Premium
XNAS:ACUR Economic Moat
Premium
XNAS:ACUR Stewardship
Premium
 

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20649

 

 

  

Form 10-Q/A

(Amendment No. 1)

(Mark One)

þQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the quarterly period ended June 30, 2012

 

or

 

¨TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________________ to_______________________

 

Commission File Number 1-10113

 

 

 

Acura Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

New York   11-0853640
(State or other Jurisdiction of   (I.R.S. Employer Identification No.)
incorporation or organization)    
     
616 N. North Court, Suite 120    
Palatine, Illinois   60067
(Address of Principal Executive Offices)   (Zip Code)

 

847 705 7709

(Registrant's telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report.)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 S-T (§232.405 of this charter) during the preceding 12 months (or to such shorter period that the registrant was required to submit and post such files).

Yes þ No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large” filer, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer o Accelerated filer o
Non-accelerated filer þ Smaller reporting company o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

 

As of July 27, 2012 the registrant had 45,863,422 shares of common stock, $.01 par value, outstanding.

 

 

 

 
 

 

AMENDMENT NO. 1 TO THE QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED JUNE 30, 2012

 

EXPLANATORY NOTE

 

The purpose of this Amendment No. 1 to our Quarterly Report on Form 10-Q for the period ended June 30, 2012 as filed with the Securities and Exchange Commission on July 30, 2012 is to furnish Exhibits 101 to the Form 10-Q as required by Rule 405 of Regulation S-T within the 30 day grace period provided by Rule 405(a)(2)(ii) of Regulation S-T.

 

No changes have been made to the Quarterly Report other than the furnishing of Exhibit 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB and 101.PRE described above. This Amendment No. 1 to Form 10-Q does not reflect subsequent events occurring after the original filing date of the Form 10-Q or modify or update in any way disclosures made in the Form 10-Q, as amended.

 

1
 

 

Item 6. Exhibits

 

The exhibits required by this Item are listed below and have been previously filed except where indicated.

 

31.1Certification of Periodic Report by Chief Executive Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934.

 

31.2Certification of Periodic Report by Chief Financial Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934.

 

32.1Certification of Periodic Report by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

*101.INSXBRL Instance Document

 

*101.SCHXBRL Taxonomy Extension Schema Document

 

*101.CALXBRL Taxonomy Extension Calculation Linkbase

 

*101.LABXBRL Taxonomy Extension Label Linkbase

 

*101.PREXBRL Taxonomy Extension Presentation Linkbase

 

*101.DEFXBRL Taxonomy Extension Definition Linkbase

 

* Furnished (Not Filed) Herewith

 

2
 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

August 9, 2012 ACURA PHARMACEUTICALS, INC.
   
  /s/ Robert B. Jones
       Robert B. Jones
       Chief Executive Officer
   
  /s/ Peter A. Clemens
       Peter A. Clemens
       Senior VP & Chief Financial Officer

  

3

XNAS:ACUR Acura Pharmaceuticals Inc Quarterly Report 10-Q/A Filling

Acura Pharmaceuticals Inc XNAS:ACUR Stock - Get Quarterly Report SEC Filing of Acura Pharmaceuticals Inc XNAS:ACUR stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

XNAS:ACUR Acura Pharmaceuticals Inc Quarterly Report 10-Q/A Filing - 6/30/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:ACUR Acura Pharmaceuticals Inc Quarterly Report 10-Q Filing - 6/30/2012  |  Next: XNAS:ACXM Acxiom Corp Annual Report 10-K Filing - 3/31/2012